Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Catabasis Pharma (CATB)

Catabasis Pharma (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 88,657
  • Shares Outstanding, K 11,499
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,870 K
  • 60-Month Beta 1.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.56
  • Number of Estimates 2
  • High Estimate -0.54
  • Low Estimate -0.58
  • Prior Year -2.00
  • Growth Rate Est. (year over year) +72.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.67 +32.10%
on 06/11/19
8.14 -7.99%
on 06/24/19
+0.20 (+2.74%)
since 05/24/19
3-Month
5.67 +32.10%
on 06/11/19
9.76 -23.26%
on 04/11/19
+0.24 (+3.31%)
since 03/25/19
52-Week
3.60 +108.06%
on 12/27/18
10.40 -27.98%
on 06/29/18
-2.01 (-21.16%)
since 06/25/18

Most Recent Stories

More News
Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved bone health with edasalonexent in contrast to negative...

CATB : 7.46 (-3.24%)
Catabasis Pharmaceuticals Reports First Quarter 2019 Financial Results and Reviews Business Progress

-- Sustained Slowing of DMD Disease Progression with Edasalonexent Reinforced by Long Term MoveDMD MRI Data --

CATB : 7.46 (-3.24%)
Catabasis Pharmaceuticals to Present Data from the MoveDMD(R) trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data on edasalonexent treatment in boys affected by...

CATB : 7.46 (-3.24%)
Catabasis Pharmaceuticals to Report First Quarter 2019 Financial Results and Recent Corporate Developments on Tuesday, May 14th

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2019 financial results before the Nasdaq Global Market open on...

CATB : 7.46 (-3.24%)
Top Ranked Momentum Stocks to Buy for April 12th

Top Ranked Momentum Stocks to Buy for April 12th

AAON : 48.30 (-0.39%)
CATB : 7.46 (-3.24%)
ACIW : 32.53 (+0.28%)
Research Report Identifies TTM Technologies, Zumiez, Global Net Lease, Catabasis Pharmaceuticals, BioPharmX, and Protalix BioTherapeutics with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TTM Technologies, Inc. (NASDAQ:TTMI),...

ZUMZ : 24.89 (-1.93%)
CATB : 7.46 (-3.24%)
GNL : 19.56 (+0.26%)
BPMX : 0.86 (-3.37%)
TTMI : 9.72 (-0.82%)
PLX : 0.45 (+2.27%)
Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent program data, including from the Phase...

CATB : 7.46 (-3.24%)
Sarepta (SRPT) Reports Positive Interim Results for DMD Drug

Sarepta???s (SRPT) key pipeline candidate leads to statistically significant increase in dystrophin production in ESSENCE study. NDA to be filed mid-2019.

CATB : 7.46 (-3.24%)
SRPT : 127.42 (+0.06%)
BMRN : 84.67 (-1.43%)
PFE : 43.92 (+0.37%)
Proteostasis Plunges on Weak Data From Cystic Fibrosis Study

Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.

ELOX : 9.36 (+4.93%)
CATB : 7.46 (-3.24%)
PTI : 1.05 (+0.96%)
VRTX : 181.45 (+0.24%)
Will Catabasis Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Catabasis.

CATB : 7.46 (-3.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CATB with:

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Key Turning Points

2nd Resistance Point 8.42
1st Resistance Point 8.06
Last Price 7.46
1st Support Level 7.43
2nd Support Level 7.16

See More

52-Week High 10.40
Fibonacci 61.8% 7.80
Last Price 7.46
Fibonacci 50% 7.00
Fibonacci 38.2% 6.20
52-Week Low 3.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar